Harmony Biosciences Holdings, Inc. 8-K

What Happened

• On July 16, 2026 Harmony Biosciences (HRMY) issued a press release reporting its preliminary net product revenue for Q2 2026 and reaffirming its full-year 2026 net product revenue guidance. The press release is attached to the 8-K as Exhibit 99.1.
• The company also announced that Chief Financial Officer Glenn Reicin stepped down effective July 16, 2026. Harmony and Harmony Biosciences Management, Inc. entered into a Separation Agreement with Mr. Reicin providing severance and a pro-rated target bonus in accordance with his employment agreement, in exchange for a release of claims; the Separation Agreement is filed as Exhibit 10.1.
• The Board appointed Stephen Mollichella, Senior Vice President and Controller, as Interim Principal Financial Officer effective July 16, 2026. Mr. Mollichella has led the company’s accounting and reporting functions since joining in 2021.

Key Details

• Date of filing/announcements: July 16, 2026 (press release and 8-K).
• Preliminary Q2 2026 net product revenue announced (specific dollar figure provided in the company press release; see Exhibit 99.1).
• CFO change: Glenn Reicin resigns effective July 16, 2026; separation includes severance and a pro‑rated target bonus per his employment agreement (see Exhibit 10.1).
• Interim finance lead: Stephen Mollichella named Interim Principal Financial Officer; no related-party transactions disclosed.

Why It Matters

• Revenue update: A preliminary Q2 revenue announcement and reaffirmed 2026 guidance give investors an early read on recent sales performance and management’s outlook for the year.
• Leadership change: The CFO’s departure is a material executive change; the company named an internal interim CFO, which supports continuity in accounting, reporting and investor communications.
• Compensation and transition: The Separation Agreement indicates customary severance and bonus treatment tied to the employment agreement, and the company has documented the arrangements in the 8-K filings (Exhibits 10.1 and 99.1).